Erasca, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- ERASErasca, Inc.10Calm
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
FinishedPhase 1/2101 patientsMain results: Aug 15, 2025 - ERASErasca, Inc.0Calm
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
FinishedPhase 1/285 patientsMain results: Jul 1, 2026 - ERASErasca, Inc.0Calm
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Running, no new patientsPhase 378 patientsMain results: Apr 2028
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.